Assessing Lentiviral Cell Therapy for Cystinosis: Stephanie Cherqui, PhD

Video

The associate professor from UC San Diego discussed the ongoing phase ½ trial of CTNS-RD

"For the stem cell manufacturing, the patients come to UCSD and they go through stem cell mobilization, and we take out their white blood cells during leukapheresis. The white blood cells is transported to the good manufacturing practice facility at UCLA where the CD44 hematopoietic cells are gene modified using a lentivirus vector.”

AVROBIO is developing CTNS-RD-04, an autologous, lentiviral, CD34+ cell therapy encoding for cystinosin for the potential treatment of cystinosis. Stephanie Cherqui, PhD, associate professor, University of California – San Diego, is developing the therapy in her lab and evaluating it for safety and efficacy in an ongoing phase 1/2 trial (NCT03897361).

Cherqui presented interim data from the first 3 patients treated in the trial at the 18th Annual WORLDSymposium, February 7-11, 2022, in San Diego, California. No treatment-related adverse events (AEs) or serious AEs have been reported. All patients exhibited a decrease in white blood cell cystine and are no longer taking oral cysteamine. Promising decreases in cystine were also noted in the cornea, skin, and kidneys.

CGTLive spoke with Cherqui to learn more about the trial, including trial protocols and CTNS-RD-04's mechanism of action.

REFERENCE
Cherqui S. Hematopoietic stem cell gene therapy for cystinosis: Updated results from a phase I/II clinical trial. Presented at: 18th Annual WORLDSymposium, February 7-11, 2022; San Diego, CA. Poster #46
Recent Videos
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization
Paul Melmeyer, MPP, the executive vice president of public policy & advocacy at MDA
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization
Arun Upadhyay, PhD, the chief scientific officer and head of research, development, and Medical at Ocugen
Arun Upadhyay, PhD, the chief scientific officer and head of research, development, and Medical at Ocugen
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
Barry J. Byrne, MD, PhD, the chief medical advisor of Muscular Dystrophy Association (MDA) and a physician-scientist at the University of Florida
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
Related Content
© 2024 MJH Life Sciences

All rights reserved.